An individualized, multifactorial approach to treating type 2 diabetic patients is recommended, including lifestyle modifications and drug therapies with new diabetic agents, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, to reduce the risk of CVD and improve renal outcomes, resting blood pressure control, and lipid and glucose levels [4, 5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.